ASLN - アスラン・ファ―マシュ―ティカルズ （ASLAN Pharmaceuticals Limited） アスラン・ファ―マシュ―ティカルズASLNのチャート
ASLNの企業情報
| symbol | ASLN |
|---|---|
| 会社名 | ASLAN Pharmaceuticals Ltd （アスラン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- アスラン・ファ―マシュ―ティカルズはケイマン諸島籍のバイオ医薬品メ―カ―。臨床段階で腫瘍学を中心に、アジアで一般的な疾病や、欧米での希少疾病を対象とした治療薬の開発を手掛ける。胆道がん、胃がん、乳がん、結腸直腸がん、急性骨髄性白血病、喘息、アトピ―性皮膚炎などの候補薬を保有する。台湾、オ―ストラリア、中国に事務所を置く。本社所在地はシンガポ―ル。 ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs. |
| 本社所在地 | 190 Elgin Avenue George Town Grand Cayman KY1-9005 CYM |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 41791 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 38人 |
| url | www.aslanpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/asln |
| adr_tso | 6000000 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 7.32 |
| 時価総額（marketcap） | 43920000 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
ASLNのテクニカル分析
ASLNのニュース
Is it time to Buy before this weeks earning report ASLAN Pharmaceuticals (NASDAQ:ASLN) 2021/07/19 13:21:00 Stock Market Daily
Earnings results for ASLAN Pharmaceuticals , Analyst Opinion on ASLAN Pharmaceuticals , Earnings and Valuation of (NASDAQ:ASLN), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Is it time to Buy before this weeks earning report ASLAN Pharmaceuticals (NASDAQ:ASLN) appeared first on .
ASLAN Pharmaceuticals Ltd - ADR Shares Close the Week 20.2% Lower - Weekly Wrap 2021/07/17 17:33:37 Kwhen Finance
ASLAN Pharmaceuticals Ltd - ADR (ASLN) shares closed this week 20.2% lower than it did at the end of last week. The stock is currently up 48.6% year-to-date, up 47.0% over the past 12 months, and down 51.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Shares traded as high as $3.37 and as low as $2.71 this week.Shares closed 59.7% below its 52-week high and 115.9% above its 52-week low.Trading volume this week was 79.3% lower than the 10-day average and 48.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 5.9% lower than its 5-day moving average, 16.3% lower than its 20-day moving average, and 16.1% lower than its 90-day moving average.
Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -270.7% The company's stock price performance over the past 12 months beats the peer average by -352.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development 2021/07/13 12:03:49 Benzinga
ASLAN Pharmaceuticals (NASDAQ: ASLN ) has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt Full story available on Benzinga.com
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures 2021/07/13 11:00:00 Intrado Digital Media
Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003 Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003
Housing Starts, Wholesale Trade Featured in Canada Next Week 2021/07/09 20:54:00 Baystreet Canada
Monday U.S. Featured Earnings Simulations Plus, Inc. (NASDAQ: SLP) (Q3) EPS projected for 17 cents, compared to 20 cents in the prior-year quarter. ASLAN Pharmaceuticals (NASDAQ:ASLN) (Q1) EPS projected for loss of 11 cents, compared to loss of 10
Is it time to Buy before this weeks earning report ASLAN Pharmaceuticals (NASDAQ:ASLN) 2021/07/19 13:21:00 Stock Market Daily
Earnings results for ASLAN Pharmaceuticals , Analyst Opinion on ASLAN Pharmaceuticals , Earnings and Valuation of (NASDAQ:ASLN), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Is it time to Buy before this weeks earning report ASLAN Pharmaceuticals (NASDAQ:ASLN) appeared first on .
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development 2021/07/13 12:03:49 Benzinga
ASLAN Pharmaceuticals (NASDAQ: ASLN ) has closed a secured loan facility provided by K2 HealthVentures (K2HV). Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt Full story available on Benzinga.com
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures 2021/07/13 11:00:00 Intrado Digital Media
Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003 Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003
Housing Starts, Wholesale Trade Featured in Canada Next Week 2021/07/09 20:54:00 Baystreet Canada
Monday U.S. Featured Earnings Simulations Plus, Inc. (NASDAQ: SLP) (Q3) EPS projected for 17 cents, compared to 20 cents in the prior-year quarter. ASLAN Pharmaceuticals (NASDAQ:ASLN) (Q1) EPS projected for loss of 11 cents, compared to loss of 10
ASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies Virtual Healthcare Conference 2021/05/25 00:00:00 BioSpace
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, 1 June, 2021 at 11:30am ET. The conference will be held from 1-4 June 2021.
ASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies Virtual Healthcare Conference 2021/05/25 00:00:00 BioSpace
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, 1 June, 2021 at 11:30am ET. The conference will be held from 1-4 June 2021.
Aslan Pharmaceuticals (ASLN) Gets a Buy Rating from H.C. Wainwright 2021/05/12 10:17:15 Smarter Analyst
In a report released today, Yi Chen from H.C. The post Aslan Pharmaceuticals (ASLN) Gets a Buy Rating from H.C. Wainwright appeared first on Smarter Analyst .
Piper Sandler Trims ASLAN Pharmaceuticals (NASDAQ:ASLN) Target Price to $8.00 2021/05/11 21:34:41 Transcript Daily
ASLAN Pharmaceuticals (NASDAQ:ASLN) had its price objective dropped by analysts at Piper Sandler from $9.00 to $8.00 in a note issued to investors on Tuesday, The Fly reports. Piper Sandlers price objective points to a potential upside of 187.77% from the companys current price. Several other brokerages have also commented on ASLN. HC Wainwright raised []